NASDAQ · CHRS
Coherus Oncology, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for CHRS: Nov 09, 2026
Coherus Oncology, Inc. Common Stock is expected to report earnings on 11/09/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.22. The reported EPS for the same quarter last year was $-0.38.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.22 | $-0.21 | $-0.22 | 2 |
| Dec 2026 | $-0.21 | $-0.21 | $-0.21 | 2 |
| Mar 2027 | $-0.21 | $-0.21 | $-0.21 | 1 |
| Jun 2027 | $-0.21 | $-0.21 | $-0.21 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · RTTNews · MarketBeat · The Motley Fool- Fintel · Oct 29, 4:32 PM EDTCoherus Oncology, Inc. Reports 75% Confirmed ORR in First-Line ESCC Patients from Tagmokitug Interim Clinical DataOn October 28, 2026, Coherus Oncology, Inc. (the “Company”) issued a press release announcing the interim clinical data from the TREGCHECK™ development program evaluating tagmokitug, its investigational cytolytic CCR8 antibody, in combination with toripalimab, w
- RTTNews · Oct 29, 6:53 AM EDTCoherus' Tagmokitug Combination Shows Responses In Esophageal Cancer; Shares Fall 9% Premarket(RTTNews) – Coherus Oncology, Inc. (CHRS) on Wednesday reported interim results from its TREGCHECK program evaluating Tagmokitug combinations, supporting expanded enrollment in first- and second-line esophageal squamous cell carcinoma cohorts.
- MarketBeat · Oct 28, 8:04 PM EDTCoherus Oncology Reports 89% Response Rate in Early ESCC StudyCoherus Oncology (NASDAQ:CHRS) presented interim clinical data for tagmokitug, an investigational therapy designed to target CCR8-positive regulatory T cells, in several solid-tumor settings. The company highlighted early activity in esophageal squamous cell carcinoma, or ESCC, a
- RTTNews · Aug 18, 10:28 AM EDTCoherus Oncology Jumps On Special Dividend Of Biosimilar CVRs(RTTNews) – Shares of Coherus Oncology, Inc. (CHRS), a commercial-stage oncology company, surged over 15% after the company announced a special dividend of contingent value rights, which will be distributed on a pro rata basis to company stockholders of record as of 5:00 p.m., Ne
- The Motley Fool · Aug 12, 8:31 PM EDTCoherus Oncology (CHRS) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · Aug 5, 8:04 PM EDTCoherus Oncology Q2 Earnings Call HighlightsCoherus Oncology (NASDAQ:CHRS) said it is approaching several clinical data disclosures in the second half of 2026, while reporting continued growth for its LOQTORZI treatment and lower operating expenses following the divestiture of its UDENYCA franchise. Chief Executive Office
- Zacks · Aug 5, 6:10 PM EDTCoherus Oncology (CHRS) Reports Q2 Loss, Misses Revenue EstimatesCoherus Oncology (CHRS) delivered earnings and revenue surprises of -337.50% and -45.57%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Jun 24, 3:10 AM EDTCoherus And Zumutor Begin Phase 1 Trial Of ZM008 And LOQTORZI Combination(RTTNews) – Coherus Oncology (CHRS) and Zumutor Biologics Inc have announced a clinical collaboration and supply agreement to study ZM008, a novel natural-killer (NK) checkpoint anti-LLT1 monoclonal antibody, together with LOQTORZI (toripalimab-tpzi), a next-generation PD-1 inhib
- Fintel · May 11, 7:45 PM EDTGuggenheim Initiates Coverage of Coherus Oncology (CHRS) with Buy RecommendationFintel reports that on May 11, 2026, Guggenheim initiated coverage of Coherus Oncology (NasdaqGM:CHRS) with a Buy recommendation. Analyst Price Forecast Suggests 197.17% Upside
- MarketBeat · May 11, 7:05 PM EDTCoherus Oncology Q1 Earnings Call HighlightsCoherus Oncology (NASDAQ:CHRS) said it expects revenue growth for its nasopharyngeal cancer drug LOQTORZI to build through the rest of 2026, while the company prepares for multiple clinical data readouts across its oncology pipeline later this year. On the company’s first-quarte
- The Motley Fool · May 11, 6:34 PM EDTCHRS Q1 2026 Earnings Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- Zacks · May 11, 6:05 PM EDTCoherus Oncology (CHRS) Reports Q1 Loss, Lags Revenue EstimatesCoherus Oncology (CHRS) delivered earnings and revenue surprises of -38.89% and -14.37%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Coherus Oncology, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.